Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Maravai LifeSciences HoldingsMRVI +0.47%60 Debt-to-EBITDA is 5.55 as of Mar. 2026, which is 478% above its 10-year median of 0.96. GuruFocus rates MRVI with a GF Score™ of 60/100 and a GF Value™ of $3.83 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 296 Biotechnology companies, Maravai LifeSciences Holdings ranks worse than 337837.5% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Maravai LifeSciences Holdings's Debt-to-EBITDA or its related term are showing as below:
MRVI'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.6 Med: 0.96 Max: 10.22
Current: -2.6
During the past 8 years, the highest Debt-to-EBITDA Ratio of Maravai LifeSciences Holdings was 10.22. The lowest was -2.60. And the median was 0.96.
MRVI's Debt-to-EBITDA is ranked worse than 100% of 296
companies
in the Biotechnology industry
Industry Median: 1.185
vs MRVI: -2.60
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Maravai LifeSciences Holdings Debt-to-EBITDA Related Terms
Maravai LifeSciences Holdings Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MRVI vs LBRX, AVTX, LXRX: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Maravai LifeSciences Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maravai LifeSciences Holdings Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Maravai LifeSciences Holdings's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Maravai LifeSciences Holdings (MRVI) has a Debt-to-EBITDA of 5.55 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Maravai LifeSciences Holdings. This is 478% above median its historical median of 0.96. According to the industry distribution chart, Maravai LifeSciences Holdings ranks #999999 out of 296 companies in the Biotechnology industry.
Is Maravai LifeSciences Holdings' Debt-to-EBITDA too high?
Maravai LifeSciences Holdings' current Debt-to-EBITDA of 5.55 is 478% above median its 10-year median of 0.96. The Biotechnology industry median Debt-to-EBITDA is 1.19. Maravai LifeSciences Holdings' value of 5.55 is 368.4% above this industry median. Based on the distribution chart, Maravai LifeSciences Holdings ranks #999999 out of 296 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Maravai LifeSciences Holdings has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' Debt-to-EBITDA compare to LBRX and AVTX?
According to the Biotechnology industry distribution chart, Maravai LifeSciences Holdings ranks #999999 out of 296 companies for Debt-to-EBITDA. This places Maravai LifeSciences Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.19. Maravai LifeSciences Holdings' value of 5.55 is 368.4% above this benchmark. While the company's 10-year median is 0.96 vs. the industry median of 1.19, Maravai LifeSciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.19, based on 296 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maravai LifeSciences Holdings's current Debt-to-EBITDA of 5.55 is 368.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Maravai LifeSciences Holdings. For the Biotechnology industry, the median Debt-to-EBITDA is 1.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maravai LifeSciences Holdings's current Debt-to-EBITDA is 5.55, which is 478% above median its own 10-year median of 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings (MRVI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.83, compared to a current price of $6.45 — trading 68.4% above its estimated fair value. The current Debt-to-EBITDA is 5.55, which is 478% above median its 10-year median of 0.96 and 368.4% above the Biotechnology industry median of 1.19. Maravai LifeSciences Holdings' overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MRVI), the current Debt-to-EBITDA is 5.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maravai LifeSciences Holdings (MRVI) Overvalued in 2026?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued.
The current stock price of $6.45 is trading 68.4% above its estimated GF Value™ of $3.83.
GuruFocus considers Maravai LifeSciences Holdings to be Significantly Overvalued.
Key valuation signals for MRVI:
Debt-to-EBITDA: 5.55 (478% above median its 10-year median of 0.96)
GF Value™: $3.83 vs. price of $6.45 (68.4% above fair value)
Industry Position: 368.4% above the Biotechnology median (#999999 of 296)
No single metric tells the full story. See the MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
60GF Score
Get the complete analysis for MRVI
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRVI has been successfully added to your 
